ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

netarsudil

Also written as “AR-13324 Ophthalmic Solution 0.02%”, “Netarsudil Ophthalmic Solution 0.02%” and “Netarsudil ophthalmic solution 0.02%”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Fuchs' Endothelial Dystrophy · Corneal Edema, led by 2 companies.

Drug pageNetarsudil: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 10, 201920 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alconits history only180 open or runningphase 4since Jan 10, 2019Feb 5, 2012none ahead
Price Vision Group20 open or runningphase 3since May 30, 2019May 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Price Vision Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named netarsudilINNProposed as its International Nonproprietary Name in WHO's List 113
  2. May 30, 2019First study: phase 3 study in Fuchs' Endothelial DystrophyFirst studyNCT03971357 · 19 enrolled · United States
  3. Aug 7, 2019Phase 3 study in Fuchs' Endothelial DystrophyNCT04051463 · 29 enrolled · United States

TargetBeta

ROCK1 →ROCK2 →read by rule
“Rho-associated protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
belumosudilruleSanofiphase 426

Studies

All 2 Price Vision Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04051463Fuchs' Endothelial Dystrophy · United States3CompletedJul 1, 202029
NCT03971357Fuchs' Endothelial Dystrophy · United States3TerminatedAug 26, 202119

How it is read

Names in the registry

  • “AR-13324 Ophthalmic Solution 0.02%”, 7 entries
  • “Netarsudil Ophthalmic Solution 0.02%”, 3 entries
  • “Netarsudil ophthalmic solution 0.02%”, 2 entries
  • “Netarsudil Ophthalmic”, 2 entries
  • “AR-13324 Ophthalmic Solution 0.04%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.